Drug Trial Radar · NCT06987539
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jul 21, 2026
Primary completion
Mar 13, 2030
Study completion Mar 13, 2030
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- May 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of inebilizumab administered in pediatric participants with gMG.
Conditions
- Generalized Myasthenia Gravis
Interventions
InebilizumabDrug
Inebilizumab will be administered IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Concentration (Cmax) of InebilizumabTime frame: Up to Week 52
- Area Under the Concentration-time Curve (AUC) of InebilizumabTime frame: Up to Week 52
- Half-life (t1/2) of InebilizumabTime frame: Up to Week 52
- Clearance (CL) of InebilizumabTime frame: Up to Week 52
- Volume of Distribution at Steady State (Vss) of InebilizumabTime frame: Up to Week 52
- Change from Baseline in Cluster of Differentiation 20 (CD20)+ B-cell CountsTime frame: Baseline and Week 78
- Number of Participants Experiencing Treatment-emergent Adverse EventsTime frame: Up to Week 78
- Number of Participants Experiencing Clinically Significant Changes in Laboratory ParametersTime frame: Up to Week 78
- Number of Participants Experiencing Clinically Significant Changes in Vital SignsTime frame: Up to Week 78
Locations
14 sites in 8 countries. Site status is shown where the registry gives one.
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois · Recruiting
The Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Austin Neuromuscular Center
Austin, Texas · Recruiting
Seattle Childrens Hospital
Seattle, Washington · Recruiting
Hospital Italiano de Buenos Aires
CABA, Buenos Aires, Argentina · Recruiting
Hospital Britanico de Buenos Aires
CABA, Buenos Aires, Argentina · Recruiting
Hospital Santa Izabel
Salvador, Estado de Bahia, Brazil · Recruiting
Instituto da Crianca - Hospital das Clinicas Fmusp
São Paulo, São Paulo, Brazil · Recruiting
Hopital Armand Trousseau
Le Kremlin-Bicêtre, France · Recruiting
Azienda Ospedaliera Universitaria Meyer
Florence, Italy · Recruiting
Medicover Integrated Clinical Services Spolka Z Ograniczona Odpowiedzialnoscia
Bydgoszcz, Poland · Recruiting
Lech Szczechowski Wielospecjalistyczna Poradnia Lekarska Synapsis
Katowice, Poland · Recruiting
Hospital Universitari i Politecnic La Fe
Valencia, Spain · Recruiting
John Radcliffe Hospital
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.